Biomedical Engineering Research Topics

INCREDIBLE HEALTH INNOVATION AND VICTORY ✅ *Yes — it’s true that Swiss researchers (at ETH Zurich) are developing tiny microrobots that can travel through blood vessels and deliver drugs directly to specific targets (like clots that cause strokes). This is an active area of biomedical research with real scientific progress. Popular Science, SWI swissinfo.ch Here’s what the current research actually shows: 🧪 What the technology is Scientists at ETH Zurich in Switzerland have created magnetically guided microrobots — microscopic capsules equipped with magnetic nanoparticles that can be propelled through blood vessels using external magnetic fields. Popular Science These microrobots are spherical gel capsules loaded with drugs (such as clot-dissolving agents, antibiotics, or other therapies). The capsule can be steered precisely to a target area in the body. Swiss Innovation Once the microrobot reaches its destination, the drug payload can be released in a controlled way (for example by heating the capsule with a magnetic field so it dissolves). Swiss Innovation They have been successfully tested in realistic laboratory vessel models and in large animals such as pigs and sheep. Robotics & Automation News 🩸 What these robots can do so far ✔️ Travel through complex blood vessel networks under magnetic control ✔️ Be tracked using imaging techniques (e.g., X-ray visibility due to contrast agents) ✔️ Deliver medicine directly to the intended site ✔️ Dissolve after delivering drugs, reducing systemic side effects Swiss Innovation 🧠 What they can’t do yet ❌ These microrobots are not yet used in human clinical practice — research is still at the preclinical stage, which means lab and animal testing, not approved treatments for people yet. SWI swissinfo.ch ❌ They are not currently able to swim autonomously like independent “robots”, nor are they freely circulating on their own — they’re guided by external magnetic fields and often delivered via a catheter into the bloodstream. Robotics & Automation News 🧠 Why this matters Strokes are a major cause of death and disability worldwide because current therapies involve high doses of clot-busting drugs given systemically, which can lead to serious side effects. Targeted drug delivery via microrobots could in theory allow much lower doses delivered right where needed, potentially reducing risks and increasing effectiveness. Swiss Innovation #HEALTH #STROKES #BLOODCLOTS #ROBOTS

💎 The future of healthcare won’t be shaped by AI performance. It’ll be shaped by human perception. AI that isn’t aligned with clinical workflows will always be ignored, no matter how powerful. A recent systematic review in JMIR took on a deceptively complex question: What makes health care workers trust (or not trust) AI-based clinical decision support systems (AI-CDSSs)? 📖 Across 27 studies from 2020–2024, a clear narrative emerged, not about performance metrics or model architectures, but about relationships. Between humans and machines. Between clinicians and their own judgment. Between what’s explainable, and what’s opaque. Eight interconnected factors shape trust: 1️⃣ Transparency – not just visibility into models, but meaningful interpretability 2️⃣ Training & Familiarity – confidence is earned through hands-on experience 3️⃣ Usability – tools must fit the messy, fast-paced realities of clinical workflows 4️⃣ Clinical Reliability – trust grows with proven, consistent performance 5️⃣ Credibility – of the developers, the data, and the science behind the system 6️⃣ Ethical Alignment – legal clarity, fairness, and accountability still matter deeply 7️⃣ Human-Centered Design – because clinicians don't want to be replaced—they want to be supported 8️⃣ Customization & Control – AI must adapt to clinicians, not the other way around The review doesn’t pretend there’s a universal blueprint for trust—but it offers a human lens on what’s too often treated as a purely technical problem. Let’s design AI not just to work, but to be welcomed. #HumanAIInteraction #TrustInAI #ClinicalAI #AIEthics #ExplainableAI #SociotechnicalSystems #HealthcareAI #ResponsibleAI #HumanCenteredAI #DigitalHealth

Biomechanical Simulation: A Pure CAE Perspective How close can our simulations get to reality when the system itself is biologically complex? Biomechanical simulation is not merely about meshing geometry or running a solver. It is about capturing highly nonlinear, anisotropic, and time-dependent behavior within a numerically stable and physically consistent framework. From a computational standpoint, these models typically integrate: ✔ Finite Element Analysis (FEA) for soft tissues and structural response ✔ Computational Fluid Dynamics (CFD) for airflow and hemodynamics ✔ Fluid–Structure Interaction (FSI) for coupled fluid–tissue mechanics ✔ Multibody dynamics for kinematic systems ✔ Advanced constitutive laws (hyperelasticity, viscoelasticity, anisotropy) The real challenge is not model construction, it's model credibility: Strong variability in biological material properties Uncertain and idealized boundary conditions Large deformation, contact, and nonlinear convergence issues Limited experimental datasets for validation High numerical sensitivity to parameters and mesh density Unlike conventional mechanical components, biological systems do not come with standardized material datasheets. Correlation, parameter identification, and stability control become critical steps in the simulation workflow. The GIF from Oklahoma State University beautifully illustrates how numerical modeling can reveal transient airflow patterns in an elastic lung model, phenomena that are impossible to observe directly in vivo: https://lnkd.in/d_b3DTvT Biomechanical simulation is where advanced computational mechanics meet the complexity of life itself. #BiomechanicalSimulation #CAE #FiniteElementAnalysis #CFD #FSI #NonlinearAnalysis #ComputationalMechanics #EngineeringSimulation

🤩 Sensor Interface Circuit for Biomedical Devices & Biosensors 💥 💝 Learn How to Interface Glucose, Lactate and other Sensors with MCU 🧐 At the heart of most of these biosensors is LMP91000 by Texas Instruments which is a programmable analog front-end for use in micro-power electrochemical sensing applications. It provides a complete signal path solution between a sensor and a microcontroller that generates an output voltage proportional to the cell current. It supports multiple electrochemical sensors such as: 3-lead toxic gas sensors and 2-lead galvanic cell sensors. The core of the LMP91000 is a potentiostat circuit. It consists of a differential input amplifier used to compare the potential between the working and reference electrodes to a required working bias potential (set by the Variable Bias circuitry). The error signal is amplified and applied to the counter electrode (through the Control Amplifier - A1). Any changes in the impedance between the working and reference electrodes will cause a change in the voltage applied to the counter electrode, in order to maintain the constant voltage between working and reference electrodes. A Transimpedance Amplifier connected to the working electrode, is used to provide an output voltage that is proportional to the cell current. The working electrode is held at virtual ground (Internal ground) by the transimpedance amplifier. The potentiostat will compare the reference voltage to the desired bias potential and adjust the voltage at the counter electrode to maintain the proper working-to-reference voltage. How to build a circuit for your biomedical application? Orlando Hoilett built KickStat, a miniaturized potentiostat using LMP91000 with the processing power of the Arm Cortex-M0+ SAMD21 Microchip Technology Inc. microcontroller on a custom-designed 21.6 mm by 20.3 mm circuit board. By incorporating onboard signal processing via the SAMD21, h he achieved 1mV voltage resolution and an instrumental limit of detection of 4.5nA in a coin-sized form factor. He measured the faradaic current of an anti-cocaine aptamer using cyclic voltammetry and square wave voltammetry and demonstrated that KickStat’s response was within 0.6% of a high-end benchtop potentiostat. To further support others in electrochemical biosensors development, he has made KickStat’s design and firmware available in an online GitHub repository. 📢 KickStat Project: "KickStat: A Coin-Sized Potentiostat for High-Resolution Electrochemical Analysis" doi: https://lnkd.in/eFjdpWjQ GitHub repo: https://lnkd.in/eJAvT_kR Datasheet: https://lnkd.in/eKvkGWCt 💜 Share it with your biosensors, biomedical wearable network 👌 #biosensors #wearables #sensors #electronics #Potentiostat #lmp91000

🌀 PET vs. SPECT: What Sets Them Apart? In nuclear medicine, two powerful imaging systems take center stage — PET and SPECT. Both visualize physiological processes using radiotracers, but they differ in how they work, what they detect, and their clinical focus. Here's a clear and concise breakdown: 🔹 1. PET (Positron Emission Tomography) What it is: A scanner that detects positron-emitting tracers (e.g., ¹⁸F-FDG) to generate high-resolution metabolic images. How it works: The tracer accumulates in metabolically active tissues (like tumors). The scanner detects pairs of gamma photons from positron annihilation. Clinical uses: Cancer staging, brain imaging (e.g., dementia, epilepsy), and cardiac perfusion/metabolism studies. 🔹 2. SPECT (Single Photon Emission Computed Tomography) What it is: A rotating gamma camera that captures multiple 2D images and reconstructs 3D distributions of single-photon emitting tracers (e.g., Tc‑99m). How it works: The tracer emits gamma rays that are detected from multiple angles, producing cross-sectional images of tracer distribution. Clinical uses: Myocardial perfusion, bone scans, thyroid imaging, renal function studies, and infection localization. 🔍 Note: Most modern PET and SPECT systems are integrated with CT scanners (PET/CT, SPECT/CT), allowing both functional and anatomical imaging in a single exam — enhancing accuracy, localization, and attenuation correction.

Last month, a team of scientists and physicians achieved something extraordinary: they developed and delivered the first-ever personalized #CRISPR therapy to treat an infant with a life-threatening #raredisease — in just six months. A one-letter change in the baby’s DNA was corrected using a custom-built gene editor. The child, who was once facing the prospect of a liver transplant, is now steadily improving. It’s a powerful example of what’s becoming possible at the intersection of #science and #technology, urgency and purposeful ambition. And this isn’t an isolated win. Across labs, clinics, and companies, CRISPR is being used as a therapeutic modality to correct inherited disorders, engineer immune cells, disable viral DNA, and even edit entire chromosomes. New gene-editing systems—like TIGR-Tas, unveiled earlier this year—are expanding what’s possible in tissues or conditions where current tools fall short. Clinical results are emerging fast—and the pace of #innovation is only picking up. At Recursion, we’re also applying #geneediting tools like CRISPR beyond therapeutics—using the technology as a tool to better understand #biology at scale. By systematically “knocking out” thousands of individual genes and measuring how those changes affect cell behavior, we’re generating large, structured datasets that feed directly into #AI models. This is helping us uncover new biological relationships and power #drugdiscovery in ways that were previously unimaginable. What ties all of this together is a commitment to applying game-changing #innovation in service of real, urgent human needs. It signals a much-needed mindset shift in #healthcare and #biopharma: to move faster, think bigger, and tackle challenges once considered out of reach—and to truly deliver on the promise of #precisionmedicine. And we’re seeing this ambition in many other areas as well – just last week, for example, GRAIL announced more promising than ever performance stats for its #Galleri blood test for the early detection of 50+ types of #cancer. There’s still work ahead to ensure breakthroughs translate into broad, equitable impact. But this moment – this momentum – is worth pausing to recognize. We’re no longer just imagining a future where science works smarter and faster for patients. We’re building it.

Probably one of the most important articles in biotech AI this year...🧬👇 A new Nature Biomedical Engineering paper describes CRISPR-GPT, a large language model–driven, multi-agent system for automating CRISPR gene-editing workflows (link in the comments). ⚙️ The system coordinates multiple specialized AI agents to do these things: - Select appropriate CRISPR systems, design guide RNAs, and choose delivery methods. - Generate experimental protocols and assay plans. - Analyze results from wet-lab experiments and adapt subsequent steps. I can't stress enough the potential significance of this work, which IMO lies in the integration of computational reasoning with experimental execution, enabling “closed-loop” cycles where experiment design, execution, and analysis are connected and automated. The authors tested their agentic CRISPR-GPT system in real experiments, e.g., these: 🧬 Knockout of four genes in a human lung adenocarcinoma cell line. In the multigene knockout experiment targeting four genes (TGFβR1, SNAI1, BAX, BCL2L1) in A549 lung adenocarcinoma cells, the AI-generated protocol achieved consistently ~80% editing efficiency across all targets, as measured by NGS analysis 🧬 Activation of two genes in a human melanoma cell line. In the epigenetic activation experiments in a human melanoma cell line, the reported efficiencies were approximately 56.5% for NCR3LG1 and 90.2% for CEACAM1, based on flow cytometry comparing gRNA-edited groups versus negative controls. With this kind of agentic AI tools, it could become possible to explore larger experimental spaces more systematically and at greater speed. This really clicks with my vision of what the key role of AI systems is in drug discovery and biotech research: tying pieces together and allowing for holistic discovery vs classical reductionism (such as "target-ligand"-centric DD workflows). We outlined our ideas about this with Oleg Kucheriavyi earlier this year, in our industry report "Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond." The report is published with BioPharmaTrend.com, check it out via the link in the comments 📑 👇. Looking forward, systems like CRISPR-GPT could evolve into general-purpose lab intelligence, able to handle multi-modal data, integrate with robotics, and support continuous, iterative discovery. The space is worth watching. If you are following AI drug discovery and other deep tech trends, subscribe to Where Tech Meets Bio, a leading Substack newsletter in this niche (link in comments). Image from the article (citation in comments)

Gene editing has the potential to cure thousands of people suffering from devastating rare diseases. But the Nobel Prize-winning technology faces a basic math problem: It’s not profitable to spend millions of dollars making a drug that may only treat one person. The solution, according to gene editing pioneer David Liu and his colleagues, is to bring everyone involved together — including patients, hospitals, scientists, drug companies and manufacturers — to make each step of the process simpler, faster and cheaper. That’s the idea behind the Center for Genetic Surgery, a new nonprofit created by Liu and his fellow scientists at the Broad Institute of MIT and Harvard. It’s a radical departure from a health-care system that keeps the players separate, each with their own bill in a manner that inflates costs. If the process is made more efficient, it could be a model for treating the long tail of rare diseases that the pharmaceutical industry traditionally ignores. “Increasingly, the bottleneck for many patients is not the science, but the system,” Liu said in an interview. “It’s about trying to bring all the stakeholders into a big tent to accomplish this.” https://lnkd.in/eshhyZ_u

🇨🇭 Switzerland Built a Medical Imaging Device That Sees Without Radiation Swiss physicists have created a quantum-enhanced MRI alternative that images soft tissue using ultra-low magnetic fields — eliminating the need for high-energy radiation or massive superconducting magnets. By exploiting quantum coherence in atomic vapors, the system detects biological signals once thought impossible to measure at room temperature. It’s portable, silent, and dramatically safer for repeated use. This could transform diagnostics in remote regions, emergency zones, and long-term monitoring of brain and heart disorders — where imaging is no longer limited by infrastructure.

In new work, we lay out a vision for a high-level programming language for generative biology, which we call Proto: https://lnkd.in/ghcpbcU2. Proto composes generative and predictive models spanning DNA, RNA, proteins, ligands, and their interactions, which we use to design complex biological systems. Current biological design workflows have made tremendous advances, but are highly specialized, siloed, and hard to compose, preventing them from generating more complex functions. Unlocking multi-objective and multi-scale design is an important goal of our work. A key idea is that biological design reduces to four primitives: sequences, constraints, generators, and optimizers. Proto abstracts these primitives to enable compositionality at a high level of abstraction, where generative models bridge the gap to low-level sequences. Proto has a minimal programmatic interface in which generators produce sequences, constraints score them, and optimizers steer toward more desirable designs. Not only do we implement a software API, but also a UI and an MCP/agentic interface. We experimentally validated Proto-generated eukaryotic and prokaryotic systems spanning all modalities of the central dogma (alternatively spliced RNA introns, specific interactions involving protein repressors and DNA promoters). We also show that human steering of AI coding agents can produce Proto programs of high complexity, encoding signaling pathways, complex regulatory logic, or proteome-scale diversification. Developing Proto was also a huge engineering lift, and the current ecosystem of biological AI models involves conflicting assumptions and dependencies. We are making available an incredibly useful library of biological tools at https://lnkd.in/gV8fAsD2. You can run structure prediction, inverse folding, seq2func models, etc. all in a browser! You can also write Proto programs in a web browser, including a chat interface that helps you understand or write new programs: https://lnkd.in/ggxXqsXb. And here’s a video demo to learn more: LINK This was a project of incredible scope with an extremely bold team of Aditi Merchant, Daniel Guo, Ben Viggiano, Lucas Brennan-Almaraz, Evelyn Hur, Tina Mai, Peter Yin, Samuel King, and Euan Ashley. Excited to see what you program! Preprint: https://lnkd.in/gRDeNmY5 About: https://lnkd.in/gCzqicYc  GitHub: https://lnkd.in/gTfC5rzU  Q&A: https://lnkd.in/g6atb2UZ